Department of Medical Oncology, Hospital AC Camargo, Sao Paulo, SP, Brazil.
Leuk Lymphoma. 2011 Aug;52(8):1495-503. doi: 10.3109/10428194.2011.573032. Epub 2011 May 31.
Diffuse large B-cell lymphoma can be classified into two prognostically distinct subgroups with germinal center B-cell-like (CG) and activated B-cell-like (post-CG) characteristics, based on CD10, BCL-6, and MUM1 expression. We performed a retrospective analysis of the clinical variables of 37 patients with primary mediastinal large B-cell lymphoma and the expression of BCL-6 and MUM1 in 22 patients with available tissue. The median age was 30 years, and 70% of the patients were female. BCL-6 and MUM1 were expressed in 64% and 45% of cases, respectively. Five-year overall survival (OS) and disease-free survival (DFS) were 47% and 81%, respectively. In univariate analysis, complete response (p = 0.0001), radiation therapy (p = 0.01), International Prognostic Index (p = 0.001), and MUM1 expression (p = 0.002) correlated with OS. For this group of patients with homogeneous clinical characteristics, response to initial chemotherapy and MUM1 expression were associated with prognosis.
弥漫性大 B 细胞淋巴瘤（DLBCL）可以根据 CD10、BCL-6 和 MUM1 的表达，分为生发中心 B 细胞样（CG）和激活的 B 细胞样（post-CG）两个具有不同预后特征的亚组。我们对 37 例原发性纵隔大 B 细胞淋巴瘤患者的临床变量进行了回顾性分析，并对 22 例有组织标本的患者进行了 BCL-6 和 MUM1 的表达分析。患者的中位年龄为 30 岁，70%为女性。BCL-6 和 MUM1 的表达率分别为 64%和 45%。5 年总生存率（OS）和无病生存率（DFS）分别为 47%和 81%。单因素分析显示，完全缓解（p=0.0001）、放疗（p=0.01）、国际预后指数（p=0.001）和 MUM1 表达（p=0.002）与 OS 相关。对于这组具有同质临床特征的患者，初始化疗的反应和 MUM1 的表达与预后相关。
